Five patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2032. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2032
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2017 to 2036.
US 9,737,585
Compositions and Methods for Treatment of Intracellular Damage and Bacterial Infection
Oct 23, 2032
US 10,953,071
Compositions and Methods for Treatment of Intracellular Damage and Bacterial Infection
Jul 14, 2033
20212025202920332036
10 pending applications: term is not computable until grant.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2035 · Medium confidence
Also notable
Ends Jul 2033 · High confidence
Also notable
Ends Aug 2036 · High confidence
Mutant Peptides And Methods Of Treating Subjects Using The Same
US 11,096,987
A family of 13 related applications built on the 2021 grant. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
Compositions and Methods for Treatment of Intracellular Damage and Bacterial Infection
US 10,953,071
The earliest of the three still in force, granted 2021 and renewed since. Its term ends first, in 2033.
Compositions And Methods For The Treatment Of Neurodamage
US 11,090,355
The newest of the three, granted 2021. It anchors the portfolio to 2036, later than anything else here.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Mutant Peptides And Methods Of Treating Subjects Using The Same | 2 in force | to Sep 2035 |
| Compositions and Methods for Treatment of Intracellular Damage and Bacterial Infection | 2 in force | to Jul 2033 |
| Compositions And Methods For The Treatment Of Neurodamage | 1 in force | to Aug 2036 |
Patents held now
Soonest term end first.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,737,585 | Compositions and Methods for Treatment of Intracellular Damage and Bacterial Infection In force · High confidence | In force | High confidence | |
| US 10,953,071 | Compositions and Methods for Treatment of Intracellular Damage and Bacterial Infection In force · High confidence | In force | High confidence | |
| US 11,096,987 | Mutant Peptides And Methods Of Treating Subjects Using The Same In force · Medium confidence | In force | Medium confidence | |
| US 12,458,681 | Compositions and Method for Treating Acute Radiation Syndrome In force · Medium confidence | In force | Medium confidence | |
| US 11,090,355 | Compositions And Methods For The Treatment Of Neurodamage In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 8 patents ended · 10 applications pending · 5 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed